Levosimendan: evolution over last two decades
Keywords:Levosimendan, Heart failure, ECMO, LV dysfunction, Sepsis, Cardiorenal syndrome
Levosimendan was maiden agent at the time of its emergence, promoting inotropy mainly through calcium sensitization of cardiac troponin C (cTnC). Levosimendan seems a lucrative option but has not demonstrated a clear superiority to other inotropes in well-designed trials. We searched the PubMed database and reviewed the pertinent studies published till 2021 and summarized various trials/studies to come to a consensus regarding its indications in cardiac patients. Patients with decompensated heart failure requiring inotropic support and receiving beta-blockers represent most widely accepted indication. Levosimendan infusions are increasingly used to facilitate extracorporeal membrane oxygenation (ECMO) weaning and avoiding hospitalizations in patients with end-stage heart failure. Levosimendan doesn’t seem to have long term survival benefit in ventricular dysfunction patients undergoing surgery. The evidence supporting the role in right ventricular failure is not well-established. These lines of evidence require further investigation and their clinical significance needs to be evaluated in specifically designed prospective trials.
Papp Z, Agostoni P, Alvarez J, Bettex D, Bouchez S, Brito D, et al. Levosimendan efficacy and safety: 20 years of SIMDAX in clinical use. Card Fail Rev. 2020;6:19.
Farmakis D, Alvarez J, Gal TB, Brito D, Fedele F, Fonseca C, et al. Levosimendan beyond inotropy and acute heart failure: evidence of pleiotropic effects on the heart and other organs: an expert panel position paper. Int J Cardiol. 2016;222:303-12.
Cholley B, Caruba T, Grosjean S, Amour J, Ouattara A, Villacorta J, et al. Effect of levosimendan on low cardiac output syndrome in patients with low ejection fraction undergoing coronary artery bypass grafting with cardiopulmonary bypass: the LICORN randomized clinical trial. JAMA. 2017;318(6):548-56.
Elbadawi A, Elgendy IY, Saad M, Megaly M, Mentias A, Abuzaid AS, et al. Meta-analysis of trials on prophylactic use of levosimendan in patients undergoing cardiac surgery. Ann Thorac Surg. 2018;105(5):1403-10.
Grieshaber P, Lipp S, Arnold A, Görlach G, Wollbrück M, Roth P, et al. Impact of prophylactic administration of Levosimendan on short-term and long-term outcome in high-risk patients with severely reduced left-ventricular ejection fraction undergoing cardiac surgery-a retrospective analysis. J Cardiothorac Surg. 2016;11(1):162.
Anastasiadis K, Antonitsis P, Vranis K, Kleontas A, Asteriou C, Grosomanidis V, et al. Effectiveness of prophylactic levosimendan in patients with impaired left ventricular function undergoing coronary artery bypass grafting: a randomized pilot study. Interact Cardiovasc Thorac Surg. 2016;23(5):740-7.
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet. 2002;360(9328):196-202.
U. S. National Library of Health. Face sheet: Effect of early use of levosimendan versus placebo on top of a conventional strategy of inotrope use on a combined morbidity-mortality endpoint in patients with cardiogenic shock (LevoHeartShock). Available at: https://clinicaltrials.gov/ct2/show/NCT04020263. Accessed on 01 December 2021.
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA. 2007;297(17):1883-91.
Packer M, Colucci W, Fisher L, Massie BM, Teerlink JR, Young J, et al. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 2013;1(2):103-11.
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European society of cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.
Bhattacharjee S, Soni KD, Maitra S, Baidya DK. Levosimendan does not provide mortality benefit over dobutamine in adult patients with septic shock: A meta-analysis of randomized controlled trials. J Clin Anesth. 2017;39:67-72.
Feng F, Chen Y, Li M, Yuan JJ, Chang XN, Dong CM. Levosimendan does not reduce the mortality of critically ill adult patients with sepsis and septic shock: a meta-analysis. Chin Med J (Engl). 2019;132(10):1212-7.
Gordon AC, Santhakumaran S, Al-Beidh F, Orme RML, Perkins GD, Singer M, et al. Levosimendan to prevent acute organ dysfunction in sepsis: the LeoPARDS RCT. Southampton (UK): NIHR Journals Library; 2018.
Chang W, Xie JF, Xu JY, Yang Y. Effect of levosimendan on mortality in severe sepsis and septic shock: a meta-analysis of randomised trials. BMJ Open. 2018;8(3):019338.
Morelli A, Donati A, Ertmer C, Rehberg S, Lange M, Orecchioni A, et al. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care. 2010;14(6):232.
Wang X, Li S. Effect of small-dose levosimendan on mortality rates and organ functions in Chinese elderly patients with sepsis. Clin Interv Aging. 2017;12:917-21.
Meng JB, Hu MH, Lai ZZ, Ji C, Xu X, Zhang G, et al. Levosimendan versus dobutamine in myocardial injury patients with septic shock: a randomized controlled trial. Med Sci Monit. 2016; 22:1486-96.
Zangrillo A, Putzu A, Monaco F. Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials. J Crit Care. 2015;30:908-13.
Vaitsis J, Michalopoulou H, Thomopoulos C. Use of levosimendan in myocardial dysfunction due to sepsis. Crit Care Med. 2009;13(1):165.
Qiu J, Jia L, Hao Y, Huang S, Ma Y, Li X, et al. Efficacy and safety of levosimendan in patients with acute right heart failure: a meta-analysis. Life Sci. 2017;184:30-6.
Mishra A, Kumar B, Dutta V, Arya VK, Mishra AK. Comparative effect of levosimendan and milrinone in cardiac surgery patients with pulmonary hypertension and left ventricular dysfunction. J Cardiothorac Vasc Anesth. 2016;30(3):639-46.
Jiang R, Zhao QH, Wu WH, Zhang R, Yuan P, Gong SG, et al. Efficacy and safety of a calcium sensitizer, levosimendan, in patients with right heart failure due to pulmonary hypertension. Clin Respir J. 2018;12(4):1518-25.
Burkhoff D, Borlaug BA, Shah SJ, Zolty R, Tedford RJ, Thenappan T, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. JACC Heart Fail. 2021;9(5):360-70.
Vally S, Ferdynus C, Persichini R, Bouchet B, Braunberger E, Pinto H, et al. Impact of levosimendan on weaning from peripheral venoarterial extracorporeal membrane oxygenation in intensive care unit. Ann Intensive Care. 2019;9(1):24.
Burgos LM, Seoane L, Furmento JF, Costabel JP, Diez M, Vrancic M, et al. Effects of levosimendan on weaning and survival in adult cardiogenic shock patients with veno-arterial extracorporeal membrane oxygenation: systematic review and meta-analysis. Perfusion. 2020;35(6):484-91.
Jacky A, Rudiger A, Krüger B, Wilhelm MJ, Paal S, Seifert B, et al. Comparison of levosimendan and milrinone for ECLS weaning in patients after cardiac surgery-a retrospective before-and-after study. J Cardiothorac Vasc Anesth. 2018;32(5):2112-9.
Guilherme E, Jacquet-Lagrèze M, Pozzi M, Achana F, Armoiry X, Fellahi JL. Can levosimendan reduce ECMO weaning failure in cardiogenic shock? a COHORT study with propensity score analysis. Crit Care. 2020;24(1):442.
Kaddoura R, Omar AS, Ibrahim MIM, Alkhulaifi A, Lorusso R, Elsherbini H, et al. The effectiveness of levosimendan on veno-arterial extracorporeal membrane oxygenation management and outcome: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth. 2021:1053(21):54-9.
Ellouze O, Faure A, Radhouani M, Abou-Arab O, Besnier E, Moussa M, et al. Levosimendan in venoarterial ECMO weaning. Rational and design of a randomized double blind multicentre trial. ESC Heart Fail. 2021.
Altenberger J, Parissis JT, Costard-Jaeckle A, Winter A, Ebner C, Karavidas A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16(8):898-906.
Comín-Colet J, Manito N, Segovia-Cubero J, Delgado J, Pinilla JM, Almenar L, et al. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail. 2018;20(7):1128-36.
Fedele F, Bruno N, Brasolin B, Caira C, D'Ambrosi A, Mancone M. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281-8.
Fedele F, Karason K, Matskeplishvili S. Pharmacological approaches to cardio-renal syndrome: a role for the inodilator levosimendan. Eur Heart J Suppl. 2017;19:22-8.
Madeira M, Caetano F, Almeida I, Fernandes A, Reis L, Costa M, et al. Inotropes and cardiorenal syndrome in acute heart failure-a retrospective comparative analysis. Rev Port Cardiol. 2017;36(9):619-25.